G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$7.09 USD
0.00 (0.00%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $7.08 -0.01 (-0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for G1 Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -47.97 | -147.56 | -148.35 | -99.25 | -122.45 |
Depreciation/Amortization & Depletion | 1.99 | 2.76 | 1.58 | 1.20 | 0.36 |
Net Change from Assets/Liabilities | -5.20 | -5.31 | -8.84 | -4.08 | 6.07 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 12.85 | 21.48 | 23.50 | 18.39 | 16.45 |
Net Cash From Operating Activities | -38.34 | -128.62 | -132.11 | -83.74 | -99.57 |
Property & Equipment | 0.00 | -0.51 | 0.00 | 0.15 | -2.72 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 2.81 | -50.02 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 2.81 | -50.53 | 0.00 | 0.15 | -2.72 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -0.22 | 52.50 | 92.22 | 2.31 | 2.71 |
Issuance (Repayment) of Debt | -26.69 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 53.64 | 19.38 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -26.91 | 52.50 | 145.86 | 21.69 | 2.71 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -62.44 | -126.65 | 13.76 | -61.90 | -99.58 |
Cash at Beginning of Period | 94.91 | 221.56 | 207.81 | 269.71 | 369.29 |
Cash at End of Period | 32.47 | 94.91 | 221.56 | 207.81 | 269.71 |
Diluted Net EPS | -0.93 | -3.38 | -3.54 | -2.62 | -3.27 |
Fiscal Year End for G1 Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -15.69 | -10.22 | -47.97 | -37.09 | -18.89 |
Depreciation/Amortization & Depletion | 0.37 | 0.41 | 1.99 | 1.55 | 1.10 |
Net Change from Assets/Liabilities | -4.14 | -1.50 | -5.20 | -0.18 | -4.36 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.29 | 2.41 | 12.85 | 10.18 | 7.18 |
Net Cash From Operating Activities | -14.17 | -8.90 | -38.34 | -25.55 | -14.97 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 5.52 | 5.29 | 2.81 | 10.46 | 3.26 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 5.52 | 5.29 | 2.81 | 10.46 | 3.26 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.26 | 0.03 | -0.22 | -0.26 | -0.28 |
Issuance (Repayment) of Debt | -8.20 | -8.75 | -26.69 | -26.69 | -26.69 |
Increase (Decrease) Short-Term Debt | -0.55 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -8.49 | -8.72 | -26.91 | -26.95 | -26.97 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -17.14 | -12.33 | -62.44 | -42.03 | -38.68 |
Cash at Beginning of Period | 32.47 | 32.47 | 94.91 | 94.91 | 94.91 |
Cash at End of Period | 15.32 | 20.14 | 32.47 | 52.87 | 56.23 |
Diluted Net EPS | -0.10 | -0.20 | -0.19 | -0.35 | 0.14 |